BT1769 / Bicycle Therap - LARVOL DELTA

Comprehensive surfaceome profiling to identify and validate novel cell-surface targets in osteosarcoma. (PubMed, Mol Cancer Ther) - "The results showed BT1769 had encouraging anti-tumor activity, high affinity for its target and a favorable pharmacokinetic profile. This confirms the hypothesis that our approach identifies novel targets with significant therapeutic potential in osteosarcoma."

Journal • Hematological Disorders • Hematological Malignancies • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • CD276 • MMP14

[VIRTUAL] Integrative surfaceome profiling identifies immunotherapeutic targets in osteosarcomas (OS); Preclinical testing of BT1769, an MT1-MMP-targeted Bicycle Toxin Conjugate, in OS by the Pediatric Preclinical Testing Consortium (PPTC) (AACR 2021) - "Integrated proteomic and transcriptomic OS surfaceome profiling identified high-confidence OS cell-surface antigens as therapeutic targets. MT1-MMP was highly expressed in most OS patient samples and PDX models, and BT1769 was highly active against select OS PDX models."

IO biomarker • Late-breaking abstract • Preclinical • Ewing Sarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • CD276

Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021 (Businesswire) - “Bicycle Therapeutics…announced that for the first time, preclinical work describing the discovery of BT7480, a novel Nectin-4/CD137 tumor-targeted immune cell agonist (TICATM), will be presented virtually in a “New Drugs on the Horizon” session at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021. Additional work covering TICAs and Bicycle Toxin Conjugates® (BTCs), will also be covered in a late-breaking mini-symposium, as well as in five e-posters…Bicycle expects BT7480 to enter the clinic in the second half of 2021.”

Preclinical • Trial status • Oncology